325 related articles for article (PubMed ID: 17499358)
1. GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder.
Rowe MK; Wiest C; Chuang DM
Neurosci Biobehav Rev; 2007; 31(6):920-31. PubMed ID: 17499358
[TBL] [Abstract][Full Text] [Related]
2. Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3beta inhibition, and viral replication: a screening approach for new bipolar disorder drugs derived from the valproic acid core structure.
Eickholt BJ; Towers GJ; Ryves WJ; Eikel D; Adley K; Ylinen LM; Chadborn NH; Harwood AJ; Nau H; Williams RS
Mol Pharmacol; 2005 May; 67(5):1426-33. PubMed ID: 15687223
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. possible new GSK-3beta therapies for bipolar disorders.
Kozikowski AP; Gaisina IN; Yuan H; Petukhov PA; Blond SY; Fedolak A; Caldarone B; McGonigle P
J Am Chem Soc; 2007 Jul; 129(26):8328-32. PubMed ID: 17552518
[TBL] [Abstract][Full Text] [Related]
4. Glycogen synthase kinase-3β activity and cognitive functioning in patients with bipolar I disorder.
Munkholm K; Miskowiak KW; Jacoby AS; Vinberg M; Leme Talib L; Gattaz WF; Kessing LV
Eur Neuropsychopharmacol; 2018 Mar; 28(3):361-368. PubMed ID: 29433844
[TBL] [Abstract][Full Text] [Related]
5. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
Gould TD; Manji HK
Neuropsychopharmacology; 2005 Jul; 30(7):1223-37. PubMed ID: 15827567
[TBL] [Abstract][Full Text] [Related]
6. Lithium and Therapeutic Targeting of GSK-3.
Snitow ME; Bhansali RS; Klein PS
Cells; 2021 Jan; 10(2):. PubMed ID: 33525562
[TBL] [Abstract][Full Text] [Related]
7. Lithium and valproate act on the GSK-3β signaling pathway to reverse manic-like behavior in an animal model of mania induced by ouabain.
Valvassori SS; Dal-Pont GC; Resende WR; Jornada LK; Peterle BR; Machado AG; Farias HR; de Souza CT; Carvalho AF; Quevedo J
Neuropharmacology; 2017 May; 117():447-459. PubMed ID: 27789311
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with lithium efficacy in bipolar disorder.
Rybakowski JK
Harv Rev Psychiatry; 2014; 22(6):353-7. PubMed ID: 25377609
[TBL] [Abstract][Full Text] [Related]
9. Glycogen synthase kinase 3: an emerging therapeutic target.
Eldar-Finkelman H
Trends Mol Med; 2002 Mar; 8(3):126-32. PubMed ID: 11879773
[TBL] [Abstract][Full Text] [Related]
10. Glycogen synthase kinase-3β in patients with bipolar I disorder: results from a prospective study.
Jacoby AS; Munkholm K; Vinberg M; Joaquim HG; Talib LL; Gattaz WF; Kessing LV
Bipolar Disord; 2016 Jun; 18(4):334-41. PubMed ID: 27325150
[TBL] [Abstract][Full Text] [Related]
11. Lymphocyte Phospho-Ser-9-GSK-3β/Total GSK-3β Protein Levels Ratio Is Not Affected by Chronic Lithium or Valproate Treatment in Euthymic Patients With Bipolar Disorder.
Azab AN; Vainer E; Agam G; Bersudsky Y
J Clin Psychopharmacol; 2017 Apr; 37(2):226-230. PubMed ID: 28106616
[TBL] [Abstract][Full Text] [Related]
12. Glycogen synthase kinase-3: a target for novel bipolar disorder treatments.
Gould TD; Zarate CA; Manji HK
J Clin Psychiatry; 2004 Jan; 65(1):10-21. PubMed ID: 14744163
[TBL] [Abstract][Full Text] [Related]
13. The role of mood stabilisers in the treatment of the depressive facet of bipolar disorders.
Bourin M; Prica C
Neurosci Biobehav Rev; 2007; 31(6):963-75. PubMed ID: 17462734
[TBL] [Abstract][Full Text] [Related]
14. Glycogen synthase kinase-3beta in the platelets of patients with mood disorders: effect of treatment.
Pandey GN; Ren X; Rizavi HS; Dwivedi Y
J Psychiatr Res; 2010 Feb; 44(3):143-8. PubMed ID: 19717166
[TBL] [Abstract][Full Text] [Related]
15. The Pharmacogenomics of Bipolar Disorder study (PGBD): identification of genes for lithium response in a prospective sample.
Oedegaard KJ; Alda M; Anand A; Andreassen OA; Balaraman Y; Berrettini WH; Bhattacharjee A; Brennand KJ; Burdick KE; Calabrese JR; Calkin CV; Claasen A; Coryell WH; Craig D; DeModena A; Frye M; Gage FH; Gao K; Garnham J; Gershon E; Jakobsen P; Leckband SG; McCarthy MJ; McInnis MG; Maihofer AX; Mertens J; Morken G; Nievergelt CM; Nurnberger J; Pham S; Schoeyen H; Shekhtman T; Shilling PD; Szelinger S; Tarwater B; Yao J; Zandi PP; Kelsoe JR
BMC Psychiatry; 2016 May; 16():129. PubMed ID: 27150464
[TBL] [Abstract][Full Text] [Related]
16. Glycogen synthase kinase 3beta as a likely target for the action of lithium on circadian clocks.
Padiath QS; Paranjpe D; Jain S; Sharma VK
Chronobiol Int; 2004 Jan; 21(1):43-55. PubMed ID: 15129823
[TBL] [Abstract][Full Text] [Related]
17. TRPM2, a Susceptibility Gene for Bipolar Disorder, Regulates Glycogen Synthase Kinase-3 Activity in the Brain.
Jang Y; Lee SH; Lee B; Jung S; Khalid A; Uchida K; Tominaga M; Jeon D; Oh U
J Neurosci; 2015 Aug; 35(34):11811-23. PubMed ID: 26311765
[TBL] [Abstract][Full Text] [Related]
18. Inositol synthesis regulates the activation of GSK-3α in neuronal cells.
Ye C; Greenberg ML
J Neurochem; 2015 Apr; 133(2):273-83. PubMed ID: 25345501
[TBL] [Abstract][Full Text] [Related]
19. Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder.
Dandekar MP; Valvassori SS; Dal-Pont GC; Quevedo J
Curr Drug Metab; 2018; 19(8):663-673. PubMed ID: 29283064
[TBL] [Abstract][Full Text] [Related]
20. The Wnt signaling pathway in bipolar disorder.
Gould TD; Manji HK
Neuroscientist; 2002 Oct; 8(5):497-511. PubMed ID: 12374432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
